Recent

% | $
Quotes you view appear here for quick access.

Cellceutix Corporation Message Board

  • dooom.booom dooom.booom Dec 25, 2012 12:33 PM Flag

    Kevetrin(TM) has significant potential to be a major breakthrough in the treatment of solid tumors. !!!

    Kevetrin(TM) has significant potential to be a major breakthrough in the treatment of solid tumors.

    Studies show Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" of the Human Genome") and that Kevetrin strongly induced cell death, characterized by activation of Caspase 3 and cleavage of PARP.

    Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

    The Company's chief scientific officer, Dr. Krishna Menon is a real whiz; he played key roles in developing two blockbuster cancer drugs; Gemzar and Alimta for Eli Lilly & Co.(NYSE:LLY) (currently trading at $50 per share) back in the late 90's.

    Extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. all tests point to the fact that Kevetrin(TM) regulats the p53 pathway - long a hope of big pharma which has spent hundreds of millions of dollars researching ways to achieve this with little success.

    Recently Cellceutix filed an IND with the FDA for a Phase 1 clinical trial to test Kevetrin against a variety of different cancer types and Phase 1 trials should begin in early 2013.

    In November Cellceutix filed an IND with the FDA for a Phase 1 clinical trial to test Kevetrin against a variety of different cancer types in patients with advanced-stage cancers. Phase 1 trials for Kevetrin(TM) should begin in early 2013 !!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Have they published as to how the reactivation of P53 takes place..i.e te mechanism of action...
      " Extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. all tests point to the fact that Kevetrin(TM) regulats the p53 pathway - long a hope of big pharma which has spent hundreds of millions of dollars researching ways to achieve this with little success. "

    • Why are you confident about Kevetrin?

      Ehrlich: It is because of the p53 pathway. I could go on for quite some time about how important p53 is and how many companies have researched it over the last three decades trying to understand it and find a way to repair damaged or mutated p53 in cancer. It’s aptly dubbed name of “The Guardian Angel of the Human Genome” really says it all as it is a master regulator of cell cycles. Think about it this way: It is well documented that in at least half of all cancers, p53 is mutated or damaged and not performing its duty to regulate the life cycle of a cell; most importantly, not seeing to it that cancer cells are destroyed before they can continue to split and run rampant. We appear to have something that bridges the gap between damaged p53 and the massive amount of cancer patients it affects. Now, obviously, that is the short version. It is much more complex than that as there are different scenarios that define “wild” and “mutant” types of p53 and interactions with other proteins that delineate hundreds, if not thousands, of pathways that companies are researching. But, to the best of our knowledge, no one has collected the type of extremely promising data with their compound that we have. As biotechnology researchers, we – as well as all the other experts that have looked at Kevetrin’s data – have to be chronic cynics. That is what has driven us to test Kevetrin so extensively before heading into clinical trials. The data collected coupled with the responses that we have received from some of the brightest minds in oncology is what keeps our confidence level high at this point.

      Sentiment: Strong Buy

 
CTIX
2.580.00(0.00%)Jul 1 3:59 PMEDT